Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SLXP
CUSIP79543510
Phone+1-919-8621000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2,134.34%
Return on Equity-305.24%
Return on Assets-25.83%
Miscellaneous
EmployeesN/A
Outstanding Shares64,250,000
Market Cap$10,940.00
Salix Pharmaceuticals (NASDAQ:SLXP) Frequently Asked Questions
What is Salix Pharmaceuticals' stock symbol?
Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."
How were Salix Pharmaceuticals' earnings last quarter?
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced its quarterly earnings results on Monday, March, 2nd. The specialty pharmaceutical company reported ($2.61) EPS for the quarter, missing the Zacks' consensus estimate of ($0.29) by $2.32. The specialty pharmaceutical company had revenue of $13 million for the quarter, compared to analysts' expectations of $187.97 million. Salix Pharmaceuticals had a negative net margin of 2,134.34% and a negative return on equity of 305.24%. During the same quarter in the previous year, the company posted $1.06 earnings per share. View Salix Pharmaceuticals' Earnings History.
What is the consensus analysts' recommendation for Salix Pharmaceuticals?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Salix Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has Salix Pharmaceuticals been receiving favorable news coverage?
Headlines about SLXP stock have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Salix Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also assigned headlines about the specialty pharmaceutical company an impact score of 46.38 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Salix Pharmaceuticals?
Shares of SLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Salix Pharmaceuticals' stock price today?
One share of SLXP stock can currently be purchased for approximately $172.81.
How big of a company is Salix Pharmaceuticals?
Salix Pharmaceuticals has a market capitalization of $10.94 billion.
How can I contact Salix Pharmaceuticals?
Salix Pharmaceuticals' mailing address is 8510 Colonnade Center Dr, RALEIGH, NC 27615-3050, United States. The specialty pharmaceutical company can be reached via phone at +1-919-8621000.
MarketBeat Community Rating for Salix Pharmaceuticals (NASDAQ SLXP)
MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe SLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
